Subscribe
Israel-Hamas Conflict
US Politics
Republican Party
Halloween
Hurricanes
Donald Trump
US Economy
Election Day
Fox News
US Presidential Election
Kamala Harris
NFL
US Crime
Published

Leqembi: Alzheimer's drug from Eisai and Biogen faces setback

Summary by ARY News
The European Union’s drugs regulator has rejected Eisai and Biogen’s Leqembi treatment for early Alzheimer’s disease, saying the risk of serious brain swelling did not outweigh its small impact on slowing cognitive decline. The decision, released on Friday, is a blow to the companies as the drug faces slow take-up in the United States. Biogen’s shares fell 5% to $216.28 in early US trading. Eisai and Biogen said they will seek re-examination of …
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

AlzheimerAlzheimer
Alzheimer's DiseaseAlzheimer's Disease
European UnionEuropean Union
PakistanPakistan

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

Trending Topics
Ground News logo
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal